Results 11 to 20 of about 4,909 (178)

Efficacy of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Management of Malignant Ascites [PDF]

World Journal of Surgical Oncology, 2020
Abstract Objective: The purpose of this study is to compare the difference of clinical efficacy between conventional intraperitoneal chemotherapy and HIPEC, so as to explore the clinical application value and advantages of HIPEC. Design: A retrospective analysis was conducted on 80 patients with malignant ascites admitted to our hospital from ...
Jie Jiao, Chengzhen Li, Guanying Yu, Lei Zhang, Xiaoyan Shi, Jingdu Yan, Houjun Zhang, Peiming Guo   +7 more
openaire   +3 more sources

There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer

International Journal of Gynecological Cancer, 2022
The hype around hyperthermic intraperitoneal chemotherapy (HIPEC) started two decades ago when a randomized trial comparing surgery and HIPEC against palliative chemotherapy only in patients with colorectal cancer showed favorable results. In ovarian cancer, data from three prospective randomized controlled trials and several retrospective trials are ...
Richard Schwameis, Luis Chiva, Philipp Harter   +2 more
openaire   +3 more sources

Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer [PDF]

Cureus, 2021
Hyperthermic intraperitoneal chemotherapy (HIPEC), along with optimal cytoreductive surgery, has been debated to be a viable option for the treatment of advanced epithelial ovarian cancer with peritoneal carcinomatosis. HIPEC is associated with a direct and improved penetration of chemotherapy drugs into the affected tissue and is associated with fewer
Mishra, Mona, Singh, Nilanchali, Ghatage, Prafull   +2 more
openaire   +2 more sources

Current Status of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer (CRC). [PDF]

South Asian J Cancer
Abstract Accounting for 8.7% of global cancer deaths, colorectal cancer (CRC) is one of the leading causes of cancer-related mortality. Cytoreduction surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is part of a multimodal strategy for managing CRC.
Somashekhar SP, Surendran AK, Goyal D, Rawat S, Aggarwal S, Selvasekar C, Parikh PM.   +6 more
europepmc   +4 more sources

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Diagnostics, 2020
Hyperthermic intraperitoneal chemotherapy (HIPEC) in conjunction with cytoreductive surgery (CRS) holds promise as an adjunctive treatment strategy in malignancies affecting the peritoneal surface, effectively targeting remaining microscopic residual ...
McKayla J. Riggs, Prakash K. Pandalai, Joseph Kim, Charles S. Dietrich   +3 more
doaj   +1 more source

Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations

BMC Cancer, 2006
Background In selected patients with peritoneal carcinomatosis from colorectal cancer prognosis can be improved by hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery.
Dimmler A, Doerfer J, Pelz Joerg OW, Hohenberger W, Meyer T   +4 more
doaj   +1 more source

329 Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer [PDF]

International Journal of Gynecological Cancer, 2019
Objectives To evaluate the disease-free survival rate in patients with ovarian cancer treated with hyperthermic intraperitoneal chemotherapy (HIPEC) and to analyze the complications related to the procedure. Methods Retrospective, longitudinal observational study of patients diagnosed with ovarian cancer, who underwent cytoreduction surgery and ...
M. Salvai, R.M. Riege, J. Costa, G. Santillan, M. Rosso   +4 more
openaire   +1 more source

Role of prophylactic HIPEC in non-metastatic, serosa-invasive gastric cancer: a literature review

Pleura and Peritoneum, 2022
The role of prophylactic hyperthermic intraperitoneal chemotherapy (p-HIPEC) in serosa invasive gastric cancers without gross or microscopic peritoneal disease, to reduce the rate of peritoneal relapse is an area of ongoing research.
Kunte Aditya R., Parray Aamir M., Bhandare Manish S., Solanki Sohan Lal   +3 more
doaj   +1 more source

Perception, knowledge and protective practices for surgical staff handling antineoplastic drugs during HIPEC and PIPAC

Pleura and Peritoneum, 2022
Two surgical techniques used for peritoneal metastasis involve a risk of exposure to antineoplastic drugs (ADs): hyperthermic intraperitoneal chemotherapy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Benoist Hubert, Eveno Clarisse, Wilson Sarah, Vigneron Nicolas, Guilloit Jean-Marc, Morello Rémy, Simon Nicolas, Odou Pascal, Saint-Lorant Guillaume   +8 more
doaj   +1 more source

Determination of biochemical indicators when modeling HIPEC with cisplatin on rats

Journal of Education, Health and Sport, 2019
HIPEC (Hyperthermic intraperitoneal chemotherapy; hyperthermic intraoperative intraperitoneally chemoperfusion) is a method of treating primary and secondary peritoneal tumors.
E. D. Pykhtieieva, A. M. Tretyakov, A. I. Gozhenko, E. G. Pykhtieieva   +3 more
doaj   +3 more sources